Research Article Cites Viraffinity™ for Dengue Virus (DV) Purification

News Release

Research Article Cites Viraffinity™ for Dengue Virus (DV) Purification

MONMOUTH JUNCTION, NJ, July 27, 2016 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their virus enrichment technology for viral proteomic analyses from plasma.

The citation is:
Romain Fragnoud, Marie Flamand, Frederic Reynier, Philippe Buchy, Vasna Duong, Alexandre Pachot, Glaucia Paranhos-Baccala and Frederic Bedin. Differential proteomic analysis of virus enriched fractions obtained from plasma pools of patients with dengue fever or severe dengue. BMC Infectious Diseases (2015) 15:518.

In brief, the article’s authors report a method to compare the proteomes of virion-enriched fractions purified from plasma pools of patients with dengue fever or severe dengue. Virions were purified by ultracentrifugation combined with Viraffinity™. Following in-gel hydrolysis, peptides were analyzed by LC-MS. The article states “A technique based on ultracentifugation (Step 1) followed by concentration using…Viraffinity™, was created to obtain a fraction of plasma enriched with DV particles. A positive signal corresponding to monomeric (60 kDa) and dimeric E protein (120 KDa) was observed in the DV-infected samples, and became more intense after the Viraffinity™ step…Densitometry indicated that the protein complexity of the purified samples was reduced by roughly 350-fold compared to the unpurified samples.”. The authors conclude that the Viraffinity™ based technique of virion-enrichment allowed them to identify two host proteins that have prognostic value for classifying patients with acute dengue who are more likely to develop a severe dengue.

“We are very happy to see that not only is Viraffinity™ useful in LC-MS proteomics, but that it complements the gold-standard of enrichment using gradient ultracentrifugation. I am very pleased that the exquisite selectivity profile of Viraffinity™ was in-part the reason these researchers were able to enrich viral proteomes 350-fold from plasma!” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit:
Viraffinity™ at

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to


Dr. Swapan Roy & Matthew Kuruc
Biotech Support Group LLC
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America